2014年4月15日

Kineta宣布入学的第一主题1 b临床试验”的愿景Kineta RLB是进步的临床发展向地区希望改善获得重要的新地区医学治疗的病人没有适当的治疗方案,”丽迪雅Bartoszek说管理合伙人兼联合创始人RLB控股。RLB控股是一家投资公司,旨在揭示有价值的机会,提供社区利益和出稳定增长的态势。目前这些投资包括一系列不同的公司包括Kineta股权,简单的愿望,和纽约洋基队。“这种合作结合资源RLB控股与Kineta平移和临床发展的专业开发新型药物的候选人,解决迫切的医疗需求,”查尔斯·格尼斯说Kineta的总裁兼首席执行官。谁担任总裁克雷格·w·飞利浦Kineta RLB,补充说,“这种方法将使我们能够扩大的一些关键资产的生命周期管理Kineta组合和增加我们的发展项目的价值病人和投资者的利益。我们最初的重点将是自身免疫性疾病,一个区域只有增量尽管巨大的进步需要成千上万的儿童和成人在美国和海外。“关于RLB控股RLB控股是一家投资公司,成立于2011年由射线和丽迪雅Bartoszek谁带领公司管理合伙人。RLB奉行多元化投资战略变革在领先行业的产品和服务。RLB控股旨在揭示有价值的机会将大幅增长,也对也提供积极的经济和社会效益。选择投资包括:纽约洋基队,Solutionpoint国际马头砂&转运码头,紧缩健身房,简单的祝福和Kineta。更多的信息可在www.RLB-Holdings.com获得。 About Kineta Kineta, Inc. is a Seattle-based privately held biotechnology company specializing in clinical advancement of novel drug candidates derived from leading-edge scientific research. Our world-class scientists are pioneers in developing life-changing classes of new drugs designed to be more effective and safer than current medicines. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases and from severe pain. Our progressive business model focuses on targeting unmet medical needs and rapid achievement of important clinical milestones. For more information on Kineta, Inc. visit our website, www.Kinetabio.com . NOTICE: This press release contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, anticipated drug effects in human subjects, regulatory submissions and financial performance. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation: progress of drug development; intellectual property protection and enforcement; efficacy, and demand for our products; clinical testing and regulatory approval; changes in legislative, fiscal, and other regulatory measures; and our ability to recruit and retain scientists and other key personnel. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. Kineta, Inc.